You are here
J&J to buy Actelion for US$30b and spin off Swiss drugmaker's R&D unit
JOHNSON & JOHNSON agreed to buy Actelion Ltd for US$30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.
With the purchase, J&
CALL +65 6388 3838 EMAIL email@example.com